-
FDA Weighs Interim Access Pathway for Compounded Peptides
The FDA is reportedly exploring an interim access framework that could preserve patient access to certain compounded peptides, offering a potential bridge while longer-term regulatory decisions are finalized.
-
Antimicrobial Peptide Spray PL-5 Shows Promise in Speeding Healing of Infected Burn Wounds
A late-stage clinical trial suggests the antimicrobial peptide spray PL-5 may help infected burn wounds heal faster, offering a potential new tool against drug-resistant infections.
-
New Clinical Trial Explores Smooth Transition to Next-Generation Peptide Therapy Zenagamtide
A new study will examine how adults with overweight, obesity, or type 2 diabetes tolerate switching from tirzepatide to the investigational peptide zenagamtide, aiming to identify optimal dosing strategies.
-
New Trial Explores Peptide-Dye Combination to Help Surgeons See Cancer More Clearly
A new Phase 1 trial is testing nivolumab-IRDye800CW, a fluorescent imaging agent, to help surgeons better visualize head and neck tumors before and during surgery.
-
New Clinical Trial Compares Firsekibart to Anakinra for Adult-Onset Still’s Disease
A new study is underway to compare the investigational peptide-based therapy firsekibart against the established treatment anakinra for Adult-Onset Still’s Disease, offering hope for expanded treatment options.
-
FDA Grants Temporary Enforcement Reprieve for Peptide Compounding, Preserving Patient Access
The FDA has issued a temporary enforcement reprieve related to peptide compounding, offering compounding pharmacies continued room to operate while broader policy is finalized. The move helps preserve patient access to personalized peptide therapies in the near term.
-
Teitur Trophics Reports Successful Phase I Trial Results for Novel Peptide Therapy
Teitur Trophics announced positive outcomes from its Phase I clinical trial, marking an encouraging early step for its peptide-based therapeutic candidate. The news adds to growing momentum in peptide drug development.
-
Peptide-Based Weight Loss Treatments Continue to Gain FDA Recognition
Peptide-based medications for weight management continue to receive regulatory backing in the U.S., reflecting growing confidence in this class of therapies. The trend highlights how peptide science is reshaping options for people managing obesity and related health concerns.
-
New Clinical Trial Explores T-Cell Therapy to Fight Dangerous Viral Infections in Immunocompromised Youth
A new basket study is testing virus-specific T lymphocyte therapy to help children and young adults with weakened immune systems fight off hard-to-treat viral infections like CMV, EBV, and BK virus.
-
New Clinical Trial Explores Targeted Therapy ASP3082 for Hard-to-Treat Cancers
A new open-label study is testing ASP3082, a targeted protein-degrading compound, in patients with advanced solid tumors carrying the KRAS G12D mutation. The trial represents a promising step toward more precise cancer treatment options.